

Title (en)  
MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS  
IN THE TREATMENT OF HIV/AIDS

Title (de)  
MITTEL UND METHODEN, UM EINE ANTIRETROVIRALE PROTEASEINHIBITOR THERAPIE ZU VERFOLGEN, UND THERAPEUTISCHE  
RICHTLINIEN FÜR DIE BEHANDLUNG VON HIV/AIDS

Title (fr)  
MOYENS ET METHODES DE SUIVI D'UNE THERAPIE ANTIRETROVIRALE A BASE D'INHIBITEURS DE PROTEASES ET DECISIONS  
D'ORIENTATION THERAPEUTIQUE DANS LE TRAITEMENT DU VIH ET DU SIDA

Publication  
**EP 1322779 A4 20050420 (EN)**

Application  
**EP 01970982 A 20010914**

Priority  
• US 0128754 W 20010914  
• US 66345800 A 20000915

Abstract (en)  
[origin: WO0222076A2] This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.

IPC 1-7  
**C12Q 1/18**; **C12Q 1/68**; **C12Q 1/70**; **G01N 33/569**

IPC 8 full level  
**C12Q 1/68** (2006.01); **C12Q 1/70** (2006.01); **G01N 33/569** (2006.01); **G01N 33/573** (2006.01)

CPC (source: EP)  
**C12Q 1/6897** (2013.01); **C12Q 1/703** (2013.01); **G01N 33/56988** (2013.01); **G01N 33/573** (2013.01)

Citation (search report)  
• [PX] WO 0078996 A1 20001228 - VIROLOGIC INC [US]  
• [X] ZIERMANN R ET AL: "A MUTATION IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE, N88S, THAT CAUSES IN VITRO HYPERSENSITIVITY TO AMPRENAVIR", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 9, May 2000 (2000-05-01), pages 4414 - 4419, XP002908352, ISSN: 0022-538X  
• [DX] JACOBSEN HELMUT ET AL: "In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies", JOURNAL OF INFECTIOUS DISEASES, vol. 173, no. 6, 1996, pages 1379 - 1387, XP009040350, ISSN: 0022-1899  
• [DX] CONDRA J H ET AL: "IN VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 374, 6 April 1995 (1995-04-06), pages 569 - 571, XP001026179, ISSN: 0028-0836  
• [X] PETROPOULOS C J ET AL: "A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 44, no. 4, April 2000 (2000-04-01), pages 920 - 928, XP002962272, ISSN: 0066-4804  
• See references of WO 0222076A2

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 0222076 A2 20020321**; **WO 0222076 A3 20030327**; AU 9092301 A 20020326; CA 2422815 A1 20020321; EP 1322779 A2 20030702; EP 1322779 A4 20050420

DOCDB simple family (application)  
**US 0128754 W 20010914**; AU 9092301 A 20010914; CA 2422815 A 20010914; EP 01970982 A 20010914